Allmed Solutions Ltd.

www.almd-solutions.com

Formerly Allium Medical

High-Tech Company
Public Company

(TASE: ALMD)

TECH VERTICALS

Healthtech, Life Sciences, Medical Devices, MedTech, Stents

General Data

Sector	Medical Devices
Company Stage:	Initial Revenues
Established	2001
Number of Employees	30
Reg. Number:	abCDe

DESCRIPTION

Allmed Solutions develops, manufactures and markets minimally invasive products internationally in various medical disciplines. These innovative products serve the need for minimally invasive interventions benefiting the patient by improving their recovery process and shortening it. Allmed Medical Solutions’ products are used by physicians to treat a wide range of diseases and patients worldwide.

TECHNOLOGY

Allium has developed a proprietary stent technology platform to expedite the development of site-specific stents. Each Allium stent is designed specifically to match the site to be treated and the surrounding anatomy. This proprietary technological platform allows Allium to produce thin walled, entirely covered stents with a large lumen, comparable to the uncovered or partly covered permanent stents but with the critical advantage of removability.

Products and Phases

Product	Phase
Allium®Stents	CE Approved
A multi-patented technology platform for site-specific stenting solutions, mainly for urological and biliary indications. The Unique combination of 1 thread of self-expanding Nitinol wire, embedded in a polymeric cover give the Allium stent its unique characteristics, which make it the leading long-term urological stent in the market. This combination facilitates: A long indwelling period of up to three years, a reduction of encrustation rate, great comfort for the patient, easy insertion and removal and a unique anatomical adaptability
EndoFast Reliant™ System	FDA Approved CE Approved
The EndoFast Reliant™ System offers a minimally invasive soft tissue fixation solution for Pelvic Organ Prolapse Repair by utilizing a new trocarless, trans-vaginal, single-incision approach for repair of Pelvic Organ Prolapse.
True Leaf	Phase I
Allium Medical through its True Leaf division is developing a solution to the mitral valve regurgitation problem, affecting millions of people around the globe. To date there is still no solution for this grave medical condition, and True Leaf and its innovative approach and its experienced valve developing engineers are continuously progressing in developing and testing the new and innovative solution of artificial transcatheter valve replacement they are developing.
Gardia Wirion® (now ProCatid)	FDA Approved CE Approved
The WIRION is a distal embolic protection system comprised of an independent Filter Unit that can be delivered, locked and deployed on any commercially marketed guide wires, according to physician preference, anywhere on the wire, in minimally invasive interventional procedures. Gardia Medical’s Embolic Protection System allows the physician to use any 0.014" guide wire of choice throughout the entire procedure, cross challenging anatomies with confidence, and lock the filter on the same guide wire anywhere along the wire. 08/2019: Cardiovascular Systems Inc. (CSI) purchased Gardia's WIRION system with Allium retaining a certain aspect of the rights to the system.

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Urologists, Cardiologists, Gynicologists, Gastroenterologists and Interventional Radiologists.

	BUSINESS MODEL
	B2C

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
A4C86FE4-1F7A-E111-AC59-00155D32A403		Allmed Solutions Ltd.
B019AF39-D067-E811-80E4-00155D0B832C	Subsidiary	Allevetix Medical Ltd.	Allmed Solutions Ltd.	Ceased
C6396D25-CB83-EA11-810A-0050569A1018	Subsidiary	TruLeaf Medical Ltd.	Allmed Solutions Ltd.

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Accounting Firm

REMARKS

Date	Remark
06/07/2021	Allmed sold its stent activity (Allium) to its German distributer, Dahlhausen Holdings, for $6.1m (NIS 20m). Allmed will also receive 50% of Allium's profits in case sales will exceed $12.8m over the next three years.
01/03/2010	Allium Medical Solutions was created following a reverse merger between Allium Ltd. (originally established 2001) and Elutex. In the years following the merger it has acquired additional companies and technologies to Allium's original stent activity. In 2021 Allium Medical Solutions changed its name to Allmed Solutions and has sold Allium's stent activity. It now focuses on the activities of ProCatid (formerly Gardia Wirion), TruLeaf and Allevetix.

CONTACT INFO

Expand / Collapse All

Main Address: Caesarea, Israel

Address	2 Ha’Eshel St., Caesarea Industrial Park
POB	3081
City	Caesarea
Country	Israel
Zip	3088900

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Prof. Oz Shapira	CEO	Vaica (Chief Medical Officer)
Dr. David Milch	Co-Founder	Infinity (Director, Life Sciences)
Prof. Daniel Yachia	Co-Founder	Harmonia Medical Technologies Inc.

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Co-Founder, Allium Medical
abC Defghij	Board Member	Board Member, Allmed Solutions
abC Defghij	Board Member	Former CEO, Medtronic Israel
abC Defghij	External Director	Formerly General Manager, Israel Venture Association
abC Defghij	External Director	Head of Mergers & Acquisitions at Ormat Technologies, Inc.

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Reverse Merger

Mar. 10, 2010

Initial Revenues

abCDe

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Apr. 28, 2015	Fourth Public Offering	TASE	abCDe	abCDe
May. 04, 2014	Third Public Offering	TASE	abCDe	abCDe
Jul. 21, 2013	Second Public Offering	TASE	abCDe	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Nov. 03, 2022

Initial Revenues

abCDe

NIS 12.3m

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe	NIS 3.5m
abC Defghij	Private Investor	abCDe	NIS 8.8m

PIPE

Jul. 11, 2016

Initial Revenues

abCDe

PIPE

Nov. 12, 2015

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Institutional Investor	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe

PIPE

Sep. 10, 2015

Initial Revenues

abCDe

PIPE

Feb. 25, 2014

Initial Revenues

abCDe

Other

Jan. 30, 2012

abCDe

PIPE

Mar. 10, 2010

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Holding Company	abCDe
abC Defghij	Investment Company	abCDe	Holds 18.18% of the company
abC Defghij	Private Investor	abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jul. 01, 2014

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Bi-National Fund	abCDe

	Acquisitions made by Allmed Solutions

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Medica...	Feb. 01, 2016	abCDe	Patent & Activities (US Patent US8408214B2)
abC Defghij	Medica...	Jan. 30, 2012	abCDe	A share-swap deal. Gardia's shareholders, mainly Medica Venture Partner, will receive 13.55% of Allium, a stake with a current value of NIS 12 million. Gardia's shareholders will also receive additional Allium shares and $2.7 million in cash, subject to milestones, including the start of a clinical trial for its product, approval by the US Food and Drug Administration (FDA), and the sale of 5,000 products.
abC Defghij	Medica...	Sep. 11, 2011	abCDe	A share-swap deal.

Last Updated:	abCDe
IVC Number:	abCDe